Inclusion Criteria:

- 40-85 year old males

- Patient is newly diagnosed with clinical Stage T1a-T2c prostate cancer based on
transrectal guided extended prostate biopsy of at least 10 cores.

- Patient elects to undergo 3D mapping biopsy at our center as part of prostate cancer
management.

- Patient will read, understand and sign the informed consent agreement

- Patients must have a life expectancy of at least one year.

- Gleason score ≤ 7 (low to moderate risk 2-7) 7= 3+4

- Percentage positive core rate < 50% based on sextant or extended biopsy technique.

- Prostate Volume (PV) >15 grams.

- Negative imaging studies ( if available) during the staging period such as Bone scan,
MRI and CT scan if PSA> 10 ng.dl before initiation of the study drug

Exclusion Criteria:

- Any 5α-reductase inhibitors medications within the past 12 months before enrollment.

- Known hypersensitivity to dutasteride, or other 5α-reductase inhibitors.

- Anticipated blood donation within the next 90 days.

- Serum PSA levels of >20ng/dl.

- Clinical evidence of metastatic prostate cancer.

- Two documented urinary tract infections in the past year

- CHF, MI (within 6 months) or other symptomatic CVS disease

- Other serious diseases (hematological, hepatic, renal, respiratory or psychiatric)

- Enrollment in other studies for any disease in the past 30 days

- Significant urinary incontinence

- Diagnosis of cancer that in not considered cured, except BCC of skin

- Prior transurethral resection of the prostate with a large tissue defect.

- History of abdominoperineal resection for rectal cancer, rectal stenosis, or other
major rectal pathology

- Previous or concurrent radiotherapy, hormonal therapy or chemotherapy